The call highlighted significant clinical progress and strategic advancements, particularly in RNA editing and program developments across multiple disease areas. Financial challenges were noted with a decrease in revenue and increased expenses leading to a net loss. However, the strong cash position and regulatory advancements suggest a positive outlook.

Company Guidance

During Wave Life Sciences' Q3 2024 earnings call, the company provided several key metrics and guidance for its pipeline. They highlighted the advancement of four clinical programs, including WVE-N531 in Duchenne Muscular Dystrophy (DMD) and WVE-003 in Huntington's Disease (HD), both moving towards potential accelerated approval. Additionally, WVE-006 in Alpha-1 Antitrypsin Deficiency (AATD) aims for multi-dose RNA editing data, while WVE-007 is set for a clinical trial in obesity. For AATD, they reported a mean of 6.9 micromolar of M-AAT post single dose, emphasizing impressive durability. In DMD, interim results showed mean muscle content-adjusted dystrophin of 9% after 24 weeks. Financially, they concluded Q3 with $310.9 million in cash, projecting sufficient funds into 2027.

Successful Clinical Milestones

Wave Life Sciences delivered three positive clinical data sets, including advancements in programs for Huntington's disease (HD), obesity, and alpha-1 antitrypsin deficiency (AATD).

Financial Strength

Wave strengthened its balance sheet with $310.9 million in cash and cash equivalents, including $187.5 million from an upsized offering and an additional $28.2 million from a greenshoe option.

Positive Data for AATD Program

First-ever clinical demonstration of RNA editing in humans with WVE-006 showed 6.9 micromolar M-AAT two weeks post single dose with impressive durability.

Advancements in Obesity Treatment

Preclinical data for WVE-007 indicated potential for novel obesity treatment with effective weight loss compared to semaglutide and other benefits such as muscle mass retention.

DMD Program Progress

WVE-N531 interim analysis showed 9% mean muscle content-adjusted dystrophin in boys with DMD, with consistent expression across patients.

Regulatory Engagement for HD

FDA provided supportive initial feedback for the potential accelerated approval of WVE-003 using caudate atrophy as a biomarker.

---

Wave Life Sciences (WVE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

WVE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 09, 2018	2018 (Q2)	- / -1.23	-0.92	-33.70% (-0.31)	―	―
Nov 09, 2018	2018 (Q3)	- / -1.28	-0.94	-36.17% (-0.34)	―	―
Mar 01, 2019	2018 (Q4)	- / -1.29	-1.1	-17.27% (-0.19)	―	―
May 10, 2019	2019 (Q1)	- / -1.36	-1.26	-7.94% (-0.10)	―	―
Nov 05, 2019	2019 (Q3)	- / -1.48	-1.28	-15.62% (-0.20)	―	―
Mar 02, 2020	2019 (Q4)	- / -1.65	-1.29	-27.91% (-0.36)	―	―
May 11, 2020	2020 (Q1)	- / -1.38	-1.36	-1.47% (-0.02)	―	―
Aug 10, 2020	2020 (Q2)	- / -1.15	-1.22	5.74% (+0.07)	―	―
Nov 09, 2020	2020 (Q3)	- / -0.86	-1.48	41.89% (+0.62)	―	―
Mar 04, 2021	2020 (Q4)	- / -0.59	-1.65	64.24% (+1.06)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

WVE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 12, 2024	$16.44	$15.89	-3.35%
Aug 08, 2024	$5.98	$5.74	-4.01%
May 09, 2024	$5.85	$5.76	-1.54%
Mar 06, 2024	$4.79	$6.29	+31.32%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---